Hello Sir,
Hope you are doing well.
In order to recommend the best stock ideas to our members for their portfolios, our team does extensive research, goes through all the corporate announcements on daily basis and screens for various potential investment opportunities.
With this mail, we are starting a new initiative of sharing important stock updates we come across while performing our research. The idea is to share the summary and not recommend or share an opinion on the stock. Hope you find them useful for your own investments:
Before that, if you are interested in investing in an Agrochemical company that will benefit immensely from the ongoing rise in the prices of farm output and food inflation and where the management is expecting strong 20% + year on year growth, you can read about it here - LINK
Bajaj Consumer – On 6th Apr’22, we came across a disclosure by Nippon Life mutual fund regarding their investment in Bajaj Consumer.
It said, Nippon India recently bought 2 lakh shares of Bajaj Consumer.
What could be the reason?
Probably deep value and bottom fishing. Bajaj Consumer has been the worst performing FMCG stock and currently around the same levels as in 2012.
Source: BSE India
Suven Pharma – On 5th Apr’22, Suven Pharma approved the acquisition of Casper Pharma for Rs 155 crore.
The management mentioned the following about Casper Pharma:
- It has installed capacity of 1.2 Bn tablets
- It has ~13-acre land which can be used to ramp up the capacity to 12 Bn
- Casper's facility can generate ~ Rs 300 Cr sales annually in next 3 years
- Caper has a long term contract with a US distributor for the next 7 years
- USFDA inspection expected in next 3-6 months
- Casper has ~ 30 ANDAs planned for next 18-24 months
- Acquisition funded completely through internal accruals
Source: BSE India
Disclaimer: This is not a recommendation to buy/sell Bajaj Consumer and Suven Pharma. These updates are as announced by the companies on exchanges and only for the purpose of information.
I have personal investment in Suven Pharma. We have an ongoing recommendation on Suven since 88 odd levels and you can read the report here - LINK
If you are looking for investment opportunities do check out our premium subscriptions.
Best Regards,
Ekansh Mittal
Research Analyst
Web: https://www.katalystwealth.
SEBI Research Analyst Registration No. INH100001690
Research Analyst Details
Name: Ekansh Mittal Email Id: [email protected] Ph: +91 727 5050062
Details of Associate: Not Applicable
Analyst Certification: The Analyst certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report.
Disclaimer: https://www.
The views expressed are based solely on information available publicly and believed to be true. Investors are advised to independently evaluate the market conditions/risks involved before making any investment decision
This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Ekansh Mittal/Mittal Consulting/Katalyst Wealth is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Ekansh Mittal or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Neither Ekansh Mittal, nor its employees, agents nor representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Ekansh Mittal/Mittal Consulting or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement.
The recipients of this report should rely on their own investigations. Ekansh Mittal/Mittal Consulting and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Mittal Consulting has incorporated adequate disclosures in this document. This should, however, not be treated as endorsement of the views expressed in the report.
We submit that no material disciplinary action has been taken on Ekansh Mittal by any regulatory authority impacting Equity Research Analysis.
Disclaimer: You can access it here - LINK
Whether the research analyst or research entity or his associate or his relative has any financial interest in the subject company/companies and the nature of such financial interest – Yes, in Suven Pharma
Whether the research analyst or research entity or his associates or his relatives have actual/beneficial ownership of 1% or more securities of the subject company (at the end of the month immediately preceding the date of publication of the research report or date of the public appearance) – No
Whether the research analyst or research entity or his associate or his relative has any other material conflict of interest at the time of publication of the research report or at the time of public appearance – No
Whether it or its associates have received any compensation from the subject company in the past twelve months – No
Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past 12 months – No
Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No
Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No
Whether the subject company is or was a client during twelve months preceding the date of distribution of the research report and the types of services provided – No
Whether the research analyst has served as an officer, director or employee of the subject company – No
Whether the research analyst or research entity has been engaged in market making activity for the subject company – No